AMGN's MariTide: Can Convenience Drive its Obesity Market Share?

Amgen's MariTide is entering a competitive obesity market dominated by Novo Nordisk and Eli Lilly. The drug showed up to 20% average weight loss in phase II trials and offers a key advantage with once-monthly or less-frequent dosing compared to weekly injections from competitors. While MariTide trails competitors' efficacy and market presence, the massive obesity market projected to reach $114 billion by 2030 could support multiple players, allowing MariTide to carve out a meaningful position based on convenience and adherence.